Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals.

MLA

Roe, Catherine M., et al. “Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals.” Alzheimer Disease and Associated Disorders, vol. 31, no. 1, Jan. 2017, pp. 69–72. EBSCOhost, https://doi.org/10.1097/WAD.0000000000000154.

APA

Roe, C. M., Barco, P. P., Head, D. M., Ghoshal, N., Selsor, N., Babulal, G. M., Fierberg, R., Vernon, E. K., Shulman, N., Johnson, A., Fague, S., Xiong, C., Grant, E. A., Campbell, A., Ott, B. R., Holtzman, D. M., Benzinger, T. L. S., Fagan, A. M., Carr, D. B., & Morris, J. C. (2017). Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals. Alzheimer Disease and Associated Disorders, 31(1), 69–72. https://doi.org/10.1097/WAD.0000000000000154

Chicago

Roe, Catherine M, Peggy P Barco, Denise M Head, Nupur Ghoshal, Natalie Selsor, Ganesh M Babulal, Rebecca Fierberg, et al. 2017. “Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals.” Alzheimer Disease and Associated Disorders 31 (1): 69–72. doi:10.1097/WAD.0000000000000154.